{'fraction_non_alphanumeric': 0.01810436634717785, 'fraction_numerical': 0.009584664536741214, 'mean_word_length': 4.802469135802469, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Anesthetic Potency of Dezocine and Its Interaction with Morphine in Rats

A new partial agonist–antagonist analgesic drug, dezocine, was evaluated in rats for its anesthetic potency using a MAC-reduction model. Respiratory effects as shown by changes in PaCO2 were also analyzed. A reduction of approximately 50% in cyclopropane MAC was found with doses of 6 mg/kg or more. This is the largest reduction for any drug of this class. PaCO2 levels increased up to 52 mm Hg with doses of dezocine up to 2 mg/kg. No evidence of reversal of respiratory depression or of further respiratory depression was found with increasing dosages. Combining dezocine with morphine resulted in a further reduction in cyclopropane MAC without a significant change in PaCO2. This suggests that dezocine acts primarily on the same receptor (mu) as morphine and that this receptor activity is further modulated by effects of dezocine on a second opioid receptor.